ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Frelick To Receive ACCC Annual Award Will Leave NCI In July

March 6, 1987

Race, Age Play Role In Delay Of Surgery For Breast Cancer

December 28, 2007

FDA Grants Orphan Designation To Photofrin for Mesothelioma

December 30, 2011

Breast Cancer Progress Report Summaries

November 14, 1975

NCI’s New Policy On Costly Research

December 10, 1993

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options

April 27, 2012